Biogen Idec ready to fight off oral MS competition

Scrip

Biogen Idec ready to fight off oral MS competition
27 October 2010
Sukaina Virji

Biogen Idec has come out fighting in the face of oral competition to its multiple sclerosis treatments Tysabri and Avonex.
Profits were down for the third quarter but the company posted better than expected earnings on the back of strong Avonex (interferon beta-1a) sales.